Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI as a second opinion for stroke: a smarter path to Clot-Busting?

NCT ID NCT07785492

Disease control Sponsor: Capital Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 28, 2026 · Updated 3 times

Summary

This trial tests whether an AI tool that assists doctors in deciding about clot-busting treatment can increase the number of acute ischemic stroke patients who receive it within 24 hours of symptoms. The AI analyzes patient data and gives real-time prompts about eligibility and risks, but the doctor makes the final decision. The study involves 516 adults with acute ischemic stroke at basic hospitals in China, comparing AI-assisted care to standard care. The goal is to see if the tool improves treatment rates and patient outcomes at 90 days.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-assisted thrombolysis decision support tool
What this could lead to
If effective, this AI tool could help more stroke patients receive timely clot-busting treatment, potentially improving recovery and reducing disability.
What could go wrong
The tool is only a support—doctors make the final call. Its benefit may vary across hospitals, and the trial is not designed to prove long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 516 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years. 2. Clinical diagnosis of acute ischemic stroke. 3. Onset time (last known well) \<24 hours. 4. CT or MRI examination excluding intracerebral hemorrhage. 5. Signed informed consent by the patient or a legally authorized representative Exclusion Criteria: 1. Currently participating in another interventional clinical trial related to drugs or devices. 2. Pregnant women. 3. Has received intravenous thrombolysis at another hospital. 4. Has completed a definitive reperfusion therapy decision at another hospital and is transferred to this hospital solely for follow-up observation or rehabilitation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke, acute are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic stroke, acute

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Liuyang Jili Hospital

    RECRUITING

    Changsha, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.